Search clinical trials for: bictegravir/emtricitabine/tenofovir alafenamide

Total 599 results

Vancouver Infectious Diseases Centre

Unknown

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Drug Use | Human Immunodeficiency Virus I Infection

Canada
Valley AIDS Council
Gilead Sciences

Not yet recruiting

Advanced HIV: Outcomes for Rapid ART (AHORA)

HIV-1-infection
University of Nebraska
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE (BASE)

HIV-1-infection

United States
Fenway Community Health

Completed

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

HIV Prevention

United States
National Taiwan University Hospital
Mackay Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital and other collaborators

Unknown

Same-day Antiretroviral Therapy With BIC/F/TAF

HIV Infections

Taiwan
University of Maryland, Baltimore
Gilead Sciences

Completed

B/F/TAF Switch Study for HIV-HBV Coinfection (BEST-HBV)

Hepatitis B | HIV-1-infection

United States
Thomas Jefferson University
University of Illinois at Chicago; University of California, San Francisco; Nova... and other collaborators

Completed

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

HIV/AIDS

United States
Quest Clinical Research
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

HIV-1-infection

United States
Brigham and Women's Hospital
Boston Medical Center; Tufts Medical Center

Completed

Effects of Biktarvy on CFR in Stable HIV Patients (BETTER)

HIV

United States
Midland Research Group, Inc.
Gilead Sciences

Completed

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Human Immunodeficiency Virus

United States
University of Missouri-Columbia
Gilead Sciences

Recruiting

Accelerated ART Initiation for PWHIV Who Are Out of Care (ACCELERATE)

HIV Infections | ART | Noncompliance, Patient

United States
Fundacion SEIMC-GESIDA

Active, not recruiting

Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED) (SIMPLIFIED)

HIV Infections

Spain
Unity Health Toronto
Canadian Institutes of Health Research (CIHR); CIHR Canadian HIV Trials Network

Recruiting

Optimizing the Delivery of HIV nPEP

HIV Infections

Canada
University of Colorado, Denver
Gilead Sciences

Terminated

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV (B-HASTE)

HIV/AIDS

United States
Charlotte-Paige Rolle, MD
ViiV Healthcare

Completed

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (DYAD)

HIV I Infection

United States
East Carolina University
Janssen Scientific Affairs, LLC

Recruiting

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

HIV Infections | Obesity

United States
Instituto de Investigación Sanitaria de la Fundación...

Completed

The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection

HIV-1-infection

Spain
State University of New York at Buffalo
Gilead Sciences

Active, not recruiting

Bictegravir in the Elderly Living With HIV (BICEP)

HIV-1-infection

United States
Azienda Ospedaliera Universitaria Senese
Catholic University of the Sacred Heart; Ospedale Policlinico San Martino; Azienda... and other collaborators

Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (DOBINeuro)

HIV-1-infection

Italy
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

HIV-1 Infection

United States, Argentina, Canada, Chile, Colombia, France, Germany, Israel, Italy, Japan, South Africa, Spain, Taiwan
Anna Cruceta

Recruiting

Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection (BIC-PHI)

HIV Primary Infection

Spain
Eastern Virginia Medical School
Gilead Sciences; United States Agency for International Development (USAID); FHI... and other collaborators

Active, not recruiting

Project Engage: Oral PrEP Acceptability

Adherence, Medication | Acceptability of Health Care

South Africa, Zimbabwe
Advancing Clinical Therapeutics Globally for HIV...
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Early ART to Limit Infection and Establishment of Reservoir (EARLIER)

HIV-1 Infection

United States, Brazil, Malawi, Zimbabwe, Thailand, Peru
Saskatchewan Health Authority - Regina Area
Gilead Sciences

Unknown

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Hepatitis C, Chronic | HIV/AIDS | Bone Diseases, Metabolic | Opioid Dependence | HIV-1-infection | HCV Coinfection | Buprenorphine Dependence | Methadone Dependence | Co-infection

Canada
Janssen Sciences Ireland UC

Completed

Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination

Healthy

Belgium
Gilead Sciences

Completed

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

HIV-1 Infection

Spain, United States, France, Italy, Germany, Canada, United Kingdom, Belgium, Puerto Rico, Australia
HQ Toronto
Gilead Sciences

Active, not recruiting

Express Testing and Same-day Initiation of PrEP Study (Express-PrEP)

HIV Prevention

Canada
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-56136379 in Healthy Participants

Healthy
University of California, San Diego

Active, not recruiting

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS)

Hiv | Hormone Therapy

United States
Jiangsu Aidea Pharmaceutical Co., Ltd
Chengdu Aidea Pharmaceutical Technology Co., Ltd

Recruiting

Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants

Healthy Adult Participants

China
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

HIV Infections

United States
Hospital Italiano de Buenos Aires
Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious...

Unknown

TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)

COVID-19 | Healthcare Workers | SARS-CoV 2

Argentina
Janssen Research & Development, LLC

Completed

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Sciences Ireland UC

Completed

A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants

Healthy

Netherlands
ViiV Healthcare

Not yet recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOGUE)

HIV Infections | HIV

Spain, Poland, France, Israel, Belgium, Portugal, Germany, Italy, Argentina, Greece, Japan, Ireland, Switzerland, United Kingdom, Denmark, Sweden, Mexico
University Health Network, Toronto
Gilead Sciences; University of Modena and Reggio Emilia; San Raffaele University... and other collaborators

Completed

Bone Health in Aging HIV Infected Women (BEING)

Menopause | HIV | Osteoporosis

Canada, Italy
Merck Sharp & Dohme LLC

Completed

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
University of California, San Diego
Gilead Sciences; University at Buffalo

Completed

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

HIV

United States
Fundacion SEIMC-GESIDA
ViiV Healthcare

Active, not recruiting

DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: (PASO-DOBLE)

HIV-1-infection

Spain
Wits Health Consortium (Pty) Ltd
London School of Hygiene and Tropical Medicine; King's College London; Karolinska... and other collaborators

Completed

The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention (CHAPS)

HIV/AIDS

South Africa
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

HIV/AIDS

United States
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rapid HIV Treatment Initiation, Access and Engagement in Care

Human Immunodeficiency Virus

United States
Technical University of Munich

Completed

Dual Therapy With Boosted Darunavir + Dolutegravir (Dualis)

HIV-Infection

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (VESTED)

HIV Infections

United States, South Africa, Thailand, Botswana, Brazil, Tanzania, Zimbabwe, India, Uganda
Johns Hopkins University
Gilead Sciences

Completed

Analysis of Crushed and Whole Tablet Genvoya

Healthy Volunteers

United States
Cristina Mussini

Unknown

Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)

HIV Infections
ViiV Healthcare

Completed

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

HIV Infections

United States
University of Southern California

Active, not recruiting

Empiric Treatment for Acute HIV in the ED (EMTreatED)

Acute HIV Infection

United States
University of Colorado, Denver

Completed

The Cellular Pharmacology of F-TAF in Dried Blood Spots (TAF-DBS)

Healthy Volunteers

United States

Search clinical trials for: bictegravir/emtricitabine/tenofovir alafenamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations